Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00899574 |
Recruitment Status
:
Completed
First Posted
: May 12, 2009
Results First Posted
: May 11, 2012
Last Update Posted
: December 7, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer Breast Neoplasms | Drug: Imiquimod | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Evaluation of Imiquimod, a Topical Toll-like Receptor 7 (TLR7) Agonist in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases |
Study Start Date : | May 2009 |
Actual Primary Completion Date : | April 2011 |
Actual Study Completion Date : | June 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Imiquimod
Each treatment cycle consists of 8 weeks. Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period. Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease. |
Drug: Imiquimod
Each treatment cycle consists of 8 weeks. Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period. Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease. Other Name: Aldara
|
- Objective Response (Complete Clinical Response+ Partial Response) [ Time Frame: 9 weeks ]This is defined as percentage of patients who achieved complete clinical response or partial response at end of cycle 1 of treatment. The tumor size will be measured as lesion surface area (region of interest, ROI). The response to the treatment is then evaluated as a function of post-treatment over pre-treatment ROI, expressed in percentage. Response criteria for this study are based on European Organisation for Research and Treatment of Cancer definitions for chest wall tumors: complete clinical response: absence of any detectable residual disease; partial response: <50% of ROI change.
- Clinical Benefits [ Time Frame: 9 weeks ]This outcome measure is defined as number of patients with improvement of symptoms after 8 weeks of treatment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with biopsy-confirmed breast cancer (prior histological documentation is acceptable).
- Patients with measurable skin metastases (chest wall recurrence and/or non-chest wall skin metastases are eligible).
- Skin metastases not suitable for or patient refusing definitive surgical resection and radiation.
- (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator.
(Cohort 2) Any concurrent systemic therapy is allowed
- Age at least 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status < or = 2.
- Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol.
-
Patients must have adequate organ and bone marrow function as defined below:
- absolute neutrophil count > or = 1,500/microliter
- hemoglobin > or = 9.5 grams/deciliter
- platelets >or = 75,000/microliter
- total bilirubin < or = 1.5 X institutional upper limit of normal
- Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal
- creatinine < or = 1.5 X institutional upper limit of normal
- Informed consent.
Exclusion Criteria:
- Brain metastases unless resected or irradiated and stable > or = 8 weeks.
- Treatment with other investigational agents.
- Patients who have received radiotherapy, high-potency corticosteroids, intralesional therapy, laser therapy or surgery other than biopsy to the target area within 4 weeks prior to first dosing of study agent.
- Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent.
- Patients with an uncontrolled bleeding disorder.
- Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible.
- Patients with known immunodeficiency or receiving immunosuppressive therapies.
- History of allergic reactions to imiquimod or its excipients.
- Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnancy or lactation.
- Women of childbearing potential not using a medically acceptable means of contraception.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899574
United States, New York | |
NYU Cancer Institute | |
New York, New York, United States, 10016 |
Principal Investigator: | Sylvia Adams, MD | New York University School of Medicine |
Publications of Results:
Responsible Party: | New York University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00899574 History of Changes |
Other Study ID Numbers: |
NYU 09-0225 |
First Posted: | May 12, 2009 Key Record Dates |
Results First Posted: | May 11, 2012 |
Last Update Posted: | December 7, 2015 |
Last Verified: | November 2015 |
Keywords provided by New York University School of Medicine:
toll-like receptor toll-like receptor agonist recurrent breast cancer breast cancer metastasized to skin and/or chestwall immunomodulator |
Additional relevant MeSH terms:
Breast Neoplasms Recurrence Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Disease Attributes |
Pathologic Processes Imiquimod Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Interferon Inducers |